The Physicians Really Are Healing Themselves, With Ozempic
1 day ago · Then he started taking Ozempic, the Novo Nordisk diabetes drug that is sold under the name Wegovy for obesity. He later switched to Mounjaro, from Eli Lilly, which is sold as Zepbound for obesity.
Novo Nordisk Defends Next-Gen Obesity Drug CagriSema, …
Feb 5, 2025 · Novo plans to begin a new trial of CagriSema in the first half of 2025 which will be longer than the original 68-week study because the data suggested additional weight loss could be achieved with ...
Novo Nordisk’s next-generation weight-loss drug CagriSema
Dec 20, 2024 · Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t cleanly surpass it in...
Novo Nordisk’s New Obesity Pill Beats Wegovy In Early Trial - Forbes
Sep 11, 2024 · Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more rapid weight loss than its popular obesity injection Wegovy.
Novo Nordisk CEO says he's confident about Wegovy supply, …
6 days ago · Details about its next-generation weight loss drugs CagriSema and amycretin are also in focus. It's been a rocky few months for Novo Nordisk . 24/7 New York news stream: Watch NBC 4 free wherever ...
Novo Nordisk’s oral amycretin tops Wegovy in obesity trial
2 days ago · Novo Nordisk has been boosted by data for an oral obesity therapy, amycretin, that was more effective than injectable Wegovy at reducing weight in a clinical trial.
Prescription Weight Loss Medication | Wegovy® (semaglutide) …
Learn how Wegovy® (semaglutide) can help adults with obesity or excess weight with weight related conditions. Read Important Safety and Prescribing Info, including Boxed Warning.
Novo Nordisk Links High-Dose Wegovy to Increased Weight Loss …
Jan 17, 2025 · A high dose of Novo Nordisk’s obesity drug Wegovy caused more weight loss than the approved regimen in a Phase III trial, the company said Friday. However, the data suggest Eli Lilly’s rival GLP-1 drug Zepbound may still have an edge over Wegovy.
Novo Nordisk hails ‘remarkable’ weight loss result for dual …
Sep 11, 2024 · Novo Nordisk has lifted the lid on a phase 1 trial of its oral amylin and GLP-1 receptor co-agonist, linking the candidate to 13.1% weight loss after 12 weeks—and highlighting the potential...
Novo Nordisk Stock Jumps on Early Stage Weight-Loss Drug
Jan 24, 2025 · Novo Nordisk's (NVO) U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for its amycretin weight-loss drug.